MoonLake Immunotherapeutics financial data

Symbol
MLTX on Nasdaq
Location
Zug, Switzerland
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 25 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1236% % -62%
Debt-to-equity 33% % 787%
Return On Equity -67% % -184%
Return On Assets -50% % -122%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float $1,340,000,000 USD 18%
Weighted Average Number of Shares Outstanding, Basic 64,463,889 shares 2.5%
Weighted Average Number of Shares Outstanding, Diluted 64,463,889 shares 2.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $202,862,000 USD 80%
General and Administrative Expense $41,972,000 USD 38%
Operating Income (Loss) $244,834,000 USD -71%
Income Tax Expense (Benefit) $611,000 USD 117%
Net Income (Loss) Attributable to Parent $227,318,000 USD -91%
Earnings Per Share, Basic -3.53 USD/shares -87%
Earnings Per Share, Diluted -3.53 USD/shares -87%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $334,517,000 USD 85%
Assets, Current $421,694,000 USD -11%
Property, Plant and Equipment, Net $577,000 USD -20%
Operating Lease, Right-of-Use Asset $1,566,000 USD -46%
Other Assets, Noncurrent $596,000 USD
Assets $424,433,000 USD -11%
Employee-related Liabilities, Current $2,324,000 USD -45%
Liabilities, Current $45,478,000 USD 102%
Operating Lease, Liability, Noncurrent $374,000 USD -74%
Liabilities $119,952,000 USD 389%
Accumulated Other Comprehensive Income (Loss), Net of Tax $604,000 USD -88%
Retained Earnings (Accumulated Deficit) $462,911,000 USD -96%
Stockholders' Equity Attributable to Parent $304,481,000 USD -32%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $304,481,000 USD -33%
Liabilities and Equity $424,433,000 USD -11%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $38,140,000 USD -155%
Net Cash Provided by (Used in) Financing Activities $73,122,000 USD 43%
Net Cash Provided by (Used in) Investing Activities $56,246,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $91,140,000 USD 1153%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $334,517,000 USD 85%
Deferred Tax Assets, Valuation Allowance $51,677,000 USD 107%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.085 pure -28%
Deferred Tax Assets, Gross $51,715,000 USD 107%
Operating Lease, Liability $1,608,000 USD -43%
Depreciation $22,813 USD 593%
Payments to Acquire Property, Plant, and Equipment $35,000 USD -83%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $231,730,000 USD -99%
Lessee, Operating Lease, Liability, to be Paid $1,666,000 USD -44%
Operating Lease, Liability, Current $1,234,000 USD -10%
Lessee, Operating Lease, Liability, to be Paid, Year Two $147,000 USD -87%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,272,000 USD -13%
Operating Lease, Weighted Average Discount Rate, Percent 0.046 pure -2.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $58,000 USD -61%
Lessee, Operating Lease, Liability, to be Paid, Year Three $147,000 USD 13%
Deferred Tax Assets, Operating Loss Carryforwards $47,241,000 USD 132%
Lessee, Operating Lease, Liability, to be Paid, Year Four $100,000 USD -23%
Operating Lease, Payments $368,000 USD 1.1%
Additional Paid in Capital $766,781,000 USD 13%
Depreciation, Depletion and Amortization $378,000 USD 15%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $12,898,000 USD 77%